Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.

LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised

LabCorp (LH) delivered earnings and revenue surprises of 20.08% and 7.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Tops Q1 Earnings and Revenue Estimates

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the first quarter ended March 31, 2021 and raised 2021 guidance. “We delivered very strong results in the first quarter driven by revenue growth across both our Diagnostics and Drug Development businesses,” said Adam H. Schechter, chairman and CEO, Labcorp. “Overall revenue in our base business grew 14.6% as people continued to return to their pre-pandemic healthcare routines and

Labcorp Announces 2021 First Quarter Results

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for LabCorp (LH)

With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.

LabCorp (LH) to Report Q1 Earnings: What's in the Offing?

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Laboratory Corporation of America Holdings shares currently look attractive on fundamental momentum and valuations. Shares come in at 19x FWD FCF and trade at average -21% discount to peer median across multiples.

Laboratory Corporation Of America Holdings: Valuations, Fundamentals Make Shares Attractive

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of the Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit for small businesses, an initiative aimed at providing fast, convenient, and reliable testing for companies with as many as 120 employees. Labcorp Employer Services currently provides COVID-19 testing and vaccination services for larger organizations and communities. The small business offering enables bulk

Labcorp Launches COVID-19 Test Kits for Small Businesses to Support Return to Work and Life Safely

Cigna

Humana

When screening the market for value opportunities, one method is to pick stocks whose trailing 12-month price-to-free cash flow ratios are low compared to that of the S&P 500 Index, which stands at around 13.18 currently.

A Trio of Health Care Stock Picks

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its first quarter of 2021 financial results before the market opens on Thursday, April 29, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-898-8036 w

Labcorp to Announce First Quarter Financial Results on April 29, 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Kathryn Wengel, current Executive Vice President and Chief Global Supply Chain Officer at Johnson & Johnson, as an independent member of Labcorp's Board of Directors, effective immediately. In connection with this appointment, the Labcorp Board will expand from 9 to 10 directors. “I am pleased to welcome a renowned healthcare industry veteran like Kathy to the La

Labcorp Appoints Johnson & Johnson Executive Kathryn Wengel to the Board of Directors

Coronavirus testing play Laboratory Corporation of America is offering up a new buying opportunity. LH stock has run as much as 160% above its 2020 lows.

Coronavirus Testing Play Offers Up New Opportunity After 160% Run

LabCorp (LH) plays a critical role in terms of COVID-19-related developments as well as makes progress in other key therapeutic areas.

LabCorp (LH) Banks on Structural Review Plan for Solid Returns

LabCorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

LabCorp (LH) Moves 4.9% Higher: Will This Strength Last?

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today issued its 2019-2020 Corporate Responsibility Report: Making a Difference When It Counts. The report includes the ways in which Labcorp carries out its mission of improving health and improving lives, and charts its progress on priorities including the company's environmental, health, and safety performance, as well as its community partnerships and its commitments to advancing diversity and inc

Labcorp Lays out Priorities and Progress in Corporate Responsibility Report

Thermo Fisher Scientific

Yesterday was a rough day for risk assets after Germany announced an Easter lockdown to avoid a new acceleration in Covid-19 cases and deaths. The measures are a response to recent worrying signs of trouble in the EU in terms of vaccine distribution.

Breaking: Stocks Running on Virus Testing News (NYSE: TMO) (OTC US: ALST) (NYSE: LH)

BorgWarner

Discover

KeyCorp

Since the market bottomed out exactly a year ago amid the Covid-19 pandemic, conditions have begun to improve as the vaccine distribution continues.

4 S&P 500 Stocks That Have Soared Over the Past Year

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today issued the following statement: Labcorp continues to make progress executing our strategy and capitalizing on the power of our diagnostic and drug development businesses. We are successfully accelerating growth across our platform, while playing a critical role in the fight against COVID-19 and helping our clients develop next-generation solutions for other key therapeutic areas such as oncology, liver

Labcorp Business Update

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, was recognized by the Healthcare Businesswomen's Association (HBA) as a 2021 Luminary. This title honors the 30-plus years of Dr. Eisenberg's career, which she has dedicated to innovations in healthcare and science, as well as her efforts in the advancement of women in the industry. “I am honored to have bee

Dr. Marcia Eisenberg, Chief Scientific Officer of Labcorp Diagnostics, Named a Healthcare Businesswoman's Association Luminary

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum on Wednesday, March 24 at 2:00 p.m. ET. A live webcast of the presentation will be available via the company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences company that

Labcorp Scheduled to Speak at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum

SAN FRANCISCO--(BUSINESS WIRE)--Circle Medical, a digital-first primary care practice, will be offering a convenient at home COVID-19 self-collection test kit in partnership with Labcorp (NYSE: LH). Together with Circle Medical's primary care telemedicine service, Circle Medical's patients will now have access to an end-to-end COVID-19 testing solution that is covered by most insurance plans. This home based COVID-19 self-collection kit is now available to patients in California, New York, Texa

Circle Medical to Offer Labcorp's At Home COVID-19 Self-Collection Test and Announces Clinical Expansion to Austin and San Diego Markets

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine's list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive source for recognizing the organizations that are transforming industries and shaping society. Labcorp was cited for its leadership in science, innovation, and healthcare in the fight against COVID-19 by advancing testing, partnering with biophar

Labcorp Named to Fast Company's List of the World's Most Innovative Companies for 2021

On Wednesday, Laboratory Corporation Of America got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Covid Test Firm Labcorp Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.

Covid Test Firm Labcorp Joins Elite List Of Stocks With 95-Plus Composite Rating

CARDIFF, Wales--(BUSINESS WIRE)--TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel's cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion. The company will use both the investment and the combined ex

TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round

Encompass Health

Callaway Golf

Home Depot

HD Supply Hlds

TreeHouse Foods

Jana Partners (Trades, Portfolio), a New York-based investment firm, disclosed last week that its top four trades during the fourth quarter of 2020 featured new holdings in Laboratory Corp of America Holdings (NYSE:LH) and Treehouse Foods Inc. (NYSE:THS), a position boost in Encompass Health Corp. (NYSE:EHC) and the closure of its position in Calloway Golf Co. (NYSE:ELY).

News for Labcorp Holdings Inc Stock (LH)